Simultaneous quantitative multiple primer detection of
This invention comprises a multiplex-capable oligonucleotide which is capable of hybridizing to at least one of the C. difficile tcdB, tcdC, or cdtB genes, wherein, wherein said primer consists of a sequence selected from the group consisting of SEQ ID NOS: 1 through 9, or a sequence that exhibits no more than one substitution of a base to a sequence selected from the group consisting of SEQ ID NOS: 1 through 9 and method for polymerase chain reaction (PCR) determining of the presence of a toxigenic strain of C. difficile in a biological sample utilizing said probes.
1. A multiplex-capable oligonucleotide which is capable of hybridizing to at least one of the C. difficile tcdB, tcdC, or cdtB genes, wherein said oligonucleotide consists of a sequence including at least two primers selected from the group consisting of SEQ ID NOS: 1 through 9, or a sequence that exhibits no more than one substitution of a base to a sequence selected from the group consisting of SEQ ID NOS: 1 through 9, wherein one said primer is a synthetic primer selected from the group of SEQ ID NOS: 7, 8, or 9.
2. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 1 and SEQ ID NO: 7.
3. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 2.
4. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 3.
5. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 4.
6. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 5.
7. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 6.
8. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 7.
9. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 8.
10. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 9.
11. A method for polymerase chain reaction (PCR) determining of the presence of a toxigenic strain of C. difficile in a biological sample, comprising:
a. simultaneously contacting said biological sample with at least three pair of multiplex-capable oligonucleotides each of claim 1 ;
b. amplifying target nucleic acid from said biological; and,
c. detecting the presence or amount of an amplified product(s) as an indicator of the presence of said toxigenic strain of C. difficile in said biological sample.
12. The method of claim 11 , wherein said biological sample is selected from the group consisting of stool, sputum, peripheral blood, plasma, serum, lymph nodes, respiratory tissue and exudates.
13. The method of claim 12 , wherein said biological sample is a stool sample.
14. The method of claim 11 , wherein said PCR is selected from the group consisting of AFLP, Alu-PCR, Asymmetric PCR Colony PCR, DD-PCR, Degenerate PCR, Hot-start PCR, In situ PCR, Inverse PCR Long-PCR, Multiplex PCR, Nested PCR, PCR-ELISA, PCR-RFLP, PCR-single strand conformation polymorphism (PCR-SSCP), quantitative competitive PCR (QC-PCR), rapid amplification of cDNA ends-PCR(RACE-PCR), Random Amplification of Polymorphic DNA-PCR (RAPD-PCR), Real-Time PCR, Repetitive extragenic palindromic-PCR (Rep-PCR), reverse transcriptase PCR (RT-PCR), TAIL-PCR, Touchdown PCR and Vectorette PCR.
15. The method of claim 14 , wherein said PCR is quantitative real-time PCR (QRT-PCR).
16. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 1 and SEQ ID NO: 8.
17. The multiplex-capable oligonucleotide of claim 1 consisting of SEQ ID NO 1 and SEQ ID NO: 9.